Syndax Pharmaceuticals Inc (SNDX) stock

SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 3/30

$9.45−0.09 (-0.94%)

Close on Nov 13, 2026Market cap $843.86MP/E –Yield –

Syndax Pharmaceuticals statistics

72 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: Feb 25, 2027 (estimated, during market hours)
Last ex-dividend date: No dividends
Fundamentals through: Sep 30, 2026
Share price as of: Nov 13, 2026

Valuation ratiosIndustry

Market Cap: $843.86M; $272.32M
Enterprise Value: $760.85M; $146.23M
PS Ratio: 2.91; 3.66

Enterprise valuationIndustry

EV / Sales: 2.63; 2.57

Share statisticsIndustry

Shares Outstanding: 89M; 58M
Shares Change (YoY): 2.39%; 10.8%
Shares Change (QoQ): 0.94%; 0.50%
Float: 88M; 49M
Shares Held by Insiders: 1.83%; 11.7%
Shares Held by Institutions: 121.1%; 56.4%

Short sellingIndustry

Short Interest: 19M; –
Short Interest Change: 5.10%; -0.80%
Short % of Float: 21.6%; 9.01%
Short % of Shares Outstanding: 21.2%; 6.30%
Days to Cover: 6.41; 5.15

Stock price statisticsIndustry

52-Week High: $25.59; –
52-Week Low: $9.11; –
20-Day Moving Average: $11.99; –
50-Day Moving Average: $15.27; –
200-Day Moving Average: $19.72; –
Average True Range (14): $0.92; –
Price Change (1 Week): -0.94%; -1.15%
Price Change (1 Month): -30.8%; -4.87%
Price Change (3 Months): -52.2%; -21.0%
Price Change (6 Months): -53.3%; -20.6%
Price Change (YTD): -55.0%; -23.6%
Price Change (1 Year): -43.7%; -22.4%
Price Change (3 Years): -35.7%; -29.5%
Price Change (5 Years): -47.3%; -77.9%
Price Change (10 Years): -6.44%; -65.4%
Average Volume (10 Days): 5M; –
Average Volume (20 Days): 4M; –
Average Volume (90 Days): 2M; –
Relative Volume: 1.46; 0.70
Relative Strength Index (14): 26.2; 43.4
Volatility (1 Year): 57.0%; 80.1%
Beta (5 Years): 1.07; 1.07

MarginsIndustry

Operating Margin: -61.7%; -38.7%
Profit Margin: -72.3%; -31.6%
EBITDA Margin: -61.7%; -27.7%

Returns on capitalIndustry

Return on Equity (ROE): -426.4%; -49.9%
Return on Assets (ROA): -33.7%; -40.6%
Return on Capital Employed (ROCE): -31.2%; -37.9%

Financial positionIndustry

Current Ratio: 4.69; 3.30
Quick Ratio: 3.53; 2.39
Interest Coverage: -44660.00; -6.35

GrowthIndustry

Revenue Growth (YoY): 159.7%; 6.82%
Revenue Growth (5Y CAGR): 157.7%; 6.41%

EfficiencyIndustry

Asset Turnover: 0.47; 0.40
Revenue Per Employee: $972.07K; $429.29K
Profits Per Employee: -$702.96K; -$689.41K
Employee Count: 298; 74
WACC: 8.59%; 10.2%

Income statement (TTM)Industry

Revenue: $289.68M; $66.37M
Operating Income: -$178.64M; -$21.37M
Net Income: -$209.48M; -$22.35M
EBITDA: -$178.64M; -$17.21M
EPS (Diluted): -$2.36; -$0.76

Balance sheetIndustry

Cash & Short-Term Investments: $427.10M; $68.68M
Total Debt: $344.10M; $116.91M
Net Cash (Debt): $83.01M; $17.76M
Net Cash Per Share: $0.93; $0.80
Equity (Book Value): -$17.18M; $53.89M
Book Value Per Share: -$0.19; $1.50
Tangible Book Value: -$17.18M; $27.13M
Working Capital: $446.47M; $79.99M

Cash flow (TTM)Industry

Operating Cash Flow: -$177.36M; -$12.38M

Dividends and yieldsIndustry

Earnings Yield: -24.8%; -21.8%

Taxes and interestIndustry

Interest Expense: $4.00K; $2.90M
Income Tax: $433.00K; $73.00K

Scores and fair valueIndustry

Altman Z-Score: -2.28; 0.23
Piotroski F-Score: 3; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

Period	SNDX	S&P 500	Difference	SNDX per year	S&P 500 per year
1 month	-32.3%	-3.0%	−29.2 pts
3 months	-50.5%	-2.8%	−47.7 pts
Year to date	-55.0%	+11.5%	−66.5 pts
1 year	-43.3%	+13.5%	−56.7 pts
3 years	-31.8%	+77.7%	−109.5 pts	-12.0%	+21.1%
5 years	-47.3%	+72.6%	−119.9 pts	-12.0%	+11.5%
10 years	-9.5%	+308.2%	−317.6 pts	-1.0%	+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

19M SNDX shares were sold short on Oct 30, 2026, up 5.1% from the previous report, or 21.58% of the shares available to trade. At recent volumes it would take 6.4 days to buy them back. Over the last 20 sessions, 43.9% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	18,920,163	+5.1%	2,951,578	6.4
Oct 15, 2026	18,001,644	-1.3%	2,357,123	7.6
Sep 30, 2026	18,234,880	-11.7%	2,152,633	8.5
Sep 15, 2026	20,660,449	-4.7%	1,402,785	14.7
Aug 31, 2026	21,681,907	-5.3%	1,103,630	19.6
Aug 14, 2026	22,902,431	+1.0%	1,523,998	15.0
Jul 31, 2026	22,665,216	+8.9%	1,219,747	18.6
Jul 15, 2026	20,816,110	-4.6%	2,116,901	9.8
Jun 30, 2026	21,812,785	+9.9%	2,548,139	8.6
Jun 15, 2026	19,855,525	+19.3%	2,181,350	9.1
May 29, 2026	16,637,071	-23.4%	1,038,230	16.0
May 15, 2026	21,712,664	+9.0%	2,060,200	10.5

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

Where these numbers come from

Parsed from the XBRL in Syndax Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SNDX.

Compare: SNDX vs RIGL · SNDX vs IDYA · SNDX vs ZLAB · SNDX vs PBYI · SNDX vs KURA

Revenue growth159.7% · median 2.2%

Operating margin-61.7% · median -63.0%

Net margin-72.3% · median -44.9%

Company	Revenue	Growth
ZLAB	$441.73M	+0.0%
SNDX	$289.68M	+159.7%
RIGL	$288.21M	+2.2%
IDYA	$234.13M	–
PBYI	$231.83M	+9.4%
KURA	$79.31M	–

Company

Next earnings (est.): Feb 25, 2027, during market hours
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 298
Held by institutions: 100.0%
Auditor: Deloitte & Touche LLP
SEC CIK: 1395937

Advertisement
300 × 250

See a number that looks wrong?